JP2014530900A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530900A5
JP2014530900A5 JP2014537760A JP2014537760A JP2014530900A5 JP 2014530900 A5 JP2014530900 A5 JP 2014530900A5 JP 2014537760 A JP2014537760 A JP 2014537760A JP 2014537760 A JP2014537760 A JP 2014537760A JP 2014530900 A5 JP2014530900 A5 JP 2014530900A5
Authority
JP
Japan
Prior art keywords
tautomer
compound
imidazol
amine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537760A
Other languages
English (en)
Japanese (ja)
Other versions
JP5946538B2 (ja
JP2014530900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/055610 external-priority patent/WO2013061205A2/en
Publication of JP2014530900A publication Critical patent/JP2014530900A/ja
Publication of JP2014530900A5 publication Critical patent/JP2014530900A5/ja
Application granted granted Critical
Publication of JP5946538B2 publication Critical patent/JP5946538B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537760A 2011-10-26 2012-10-15 ナトリウムチャネルモジュレーターとして有用な(4−フェニルイミダゾール−2−イル)エチルアミン誘導体 Expired - Fee Related JP5946538B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
US61/551,628 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (3)

Publication Number Publication Date
JP2014530900A JP2014530900A (ja) 2014-11-20
JP2014530900A5 true JP2014530900A5 (show.php) 2015-12-03
JP5946538B2 JP5946538B2 (ja) 2016-07-06

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537760A Expired - Fee Related JP5946538B2 (ja) 2011-10-26 2012-10-15 ナトリウムチャネルモジュレーターとして有用な(4−フェニルイミダゾール−2−イル)エチルアミン誘導体

Country Status (28)

Country Link
US (1) US9079878B2 (show.php)
EP (1) EP2771335A2 (show.php)
JP (1) JP5946538B2 (show.php)
KR (1) KR101586966B1 (show.php)
CN (1) CN103906746B (show.php)
AP (1) AP2014007579A0 (show.php)
AU (1) AU2012328034B2 (show.php)
BR (1) BR112014009102A2 (show.php)
CA (1) CA2850925C (show.php)
CL (1) CL2014000956A1 (show.php)
CO (1) CO6940427A2 (show.php)
CR (1) CR20140185A (show.php)
CU (1) CU20140046A7 (show.php)
DO (1) DOP2014000085A (show.php)
EA (1) EA023375B1 (show.php)
EC (1) ECSP14013324A (show.php)
GT (1) GT201400079A (show.php)
IL (1) IL232267A (show.php)
MD (1) MD20140037A2 (show.php)
MX (1) MX337469B (show.php)
NI (1) NI201400031A (show.php)
PE (1) PE20141682A1 (show.php)
PH (1) PH12014500919A1 (show.php)
SG (1) SG11201401032YA (show.php)
TN (1) TN2014000147A1 (show.php)
UA (1) UA109220C2 (show.php)
WO (1) WO2013061205A2 (show.php)
ZA (1) ZA201402281B (show.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2755980T3 (pl) * 2011-09-14 2020-05-18 Dow Agrosciences Llc Sposoby i układy do wytwarzania kwasów boronowych i ich związków pośrednich
SI3080134T1 (sl) 2013-12-13 2018-11-30 Vertex Pharmaceuticals Incorporated Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
JP6779217B2 (ja) * 2014-10-24 2020-11-04 アヴェクタス リミテッド 細胞原形質膜を越える送達方法
KR20170117170A (ko) 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017115128A2 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CA3029132A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
AR116939A1 (es) 2018-11-02 2021-06-30 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン-2-カルボキサミド
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
BRPI0510664B8 (pt) * 2004-05-07 2021-05-25 Warner Lambert Co derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
AU2005299310A1 (en) * 2004-10-27 2006-05-04 Canji, Inc. Compositions and methods for short interfering nucleic acid inhibition of Nav1.8
HRP20160005T1 (hr) * 2005-12-22 2016-02-12 Newron Pharmaceuticals S.P.A. 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
AU2008247102B2 (en) 2007-05-03 2011-11-24 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
US20100227872A1 (en) 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors

Similar Documents

Publication Publication Date Title
JP2014530900A5 (show.php)
JP2016538313A5 (show.php)
JP2013508279A5 (show.php)
JP2006524660A5 (show.php)
JP2016526576A5 (show.php)
JP2013512277A5 (show.php)
JP2014526501A5 (show.php)
JP2014520809A5 (show.php)
JP2009535307A5 (show.php)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2011529054A5 (show.php)
JP2013510124A5 (show.php)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2018536648A5 (show.php)
JP2013544276A5 (show.php)
JP2013544860A5 (show.php)
JP2014507477A5 (show.php)
JP2020512337A5 (show.php)
JP2009543795A5 (show.php)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2010526819A5 (show.php)
JP2012530765A5 (show.php)
JP2017505293A5 (show.php)
JP2013506674A5 (show.php)
JP2019505529A5 (show.php)